KR20010033062A - 렌티바이러스성 벡터의 치료학적 용도 - Google Patents

렌티바이러스성 벡터의 치료학적 용도 Download PDF

Info

Publication number
KR20010033062A
KR20010033062A KR1020007006423A KR20007006423A KR20010033062A KR 20010033062 A KR20010033062 A KR 20010033062A KR 1020007006423 A KR1020007006423 A KR 1020007006423A KR 20007006423 A KR20007006423 A KR 20007006423A KR 20010033062 A KR20010033062 A KR 20010033062A
Authority
KR
South Korea
Prior art keywords
cells
vector
hiv
gene
lentiviral
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
KR1020007006423A
Other languages
English (en)
Korean (ko)
Inventor
루이기 낼다이니
진-핑 송
Original Assignee
루이기 낼다이니
진-핑 송
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 루이기 낼다이니, 진-핑 송 filed Critical 루이기 낼다이니
Publication of KR20010033062A publication Critical patent/KR20010033062A/ko
Withdrawn legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/76—Viruses; Subviral particles; Bacteriophages
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Virology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Molecular Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Organic Chemistry (AREA)
  • AIDS & HIV (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Genetics & Genomics (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
KR1020007006423A 1997-12-12 1998-12-11 렌티바이러스성 벡터의 치료학적 용도 Withdrawn KR20010033062A (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US6957997P 1997-12-12 1997-12-12
US60/069,579 1997-12-12
PCT/US1998/025720 WO1999030742A1 (en) 1997-12-12 1998-12-11 Therapeutic use of lentiviral vectors

Publications (1)

Publication Number Publication Date
KR20010033062A true KR20010033062A (ko) 2001-04-25

Family

ID=22089926

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020007006423A Withdrawn KR20010033062A (ko) 1997-12-12 1998-12-11 렌티바이러스성 벡터의 치료학적 용도

Country Status (6)

Country Link
EP (1) EP1037669A4 (cg-RX-API-DMAC7.html)
JP (1) JP2002508338A (cg-RX-API-DMAC7.html)
KR (1) KR20010033062A (cg-RX-API-DMAC7.html)
AU (1) AU749059B2 (cg-RX-API-DMAC7.html)
CA (1) CA2314683A1 (cg-RX-API-DMAC7.html)
WO (1) WO1999030742A1 (cg-RX-API-DMAC7.html)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2388301C (en) 1999-10-22 2011-01-04 Aventis Pasteur Limited Modified gp100 and uses thereof
US6656706B2 (en) 1999-12-23 2003-12-02 The United States Of America As Represented By The Department Of Health And Human Services Molecular clones with mutated HIV gag/pol, SIV gag and SIV env genes
US7851212B2 (en) 2000-05-10 2010-12-14 Sanofi Pasteur Limited Immunogenic polypeptides encoded by MAGE minigenes and uses thereof
US6712612B1 (en) 2000-12-12 2004-03-30 Genecure Llc Safe and stable retroviral helper cell line and related compositions and methods
WO2004060346A2 (en) 2002-12-30 2004-07-22 Angiotech International Ag Drug delivery from rapid gelling polymer composition
WO2004094642A2 (en) 2003-04-24 2004-11-04 Fondazione Centro San Raffaele Del Monte Tabor Lentiviral vectors carrying synthetic bi-directional promoters and uses thereof
WO2009049350A1 (en) 2007-10-15 2009-04-23 The University Of Queensland Expression system for modulating an immune response
US9795658B2 (en) 2010-04-20 2017-10-24 Admedus Vaccines Pty Ltd Expression system for modulating an immune response
CN108601951B (zh) 2015-12-09 2022-11-22 金港医疗(澳大利亚)私人有限公司 用于治疗的免疫调节组合物
US11285191B2 (en) 2016-07-26 2022-03-29 The Board Of Supervisors Of Louisiana State University And Agricultural And Mechanical College Immunostimulatory compositions and uses therefor

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0816507A4 (en) * 1995-03-16 1998-07-01 Hisamitsu Pharmaceutical Co NEW RECOMBINANT GEN
US5650309A (en) * 1995-05-16 1997-07-22 The Regents Of The University Of California Viral vectors
US6013516A (en) * 1995-10-06 2000-01-11 The Salk Institute For Biological Studies Vector and method of use for nucleic acid delivery to non-dividing cells
WO1997020052A1 (en) * 1995-11-28 1997-06-05 Clinical Technologies, Inc. Recombinant hiv and modified packaging cells and method for treating acquired immune deficiency syndrome
ATE455858T1 (de) * 1995-11-28 2010-02-15 Univ Johns Hopkins Med Konditionell replizierende virale vektoren und ihre verwendung
AP964A (en) * 1996-02-21 2001-05-11 Julianna Lisziewicz Methods and compositions for protective and therapeutic genetic immunisation.
CA2247091A1 (en) * 1996-03-05 1997-09-12 The Regents Of The University Of California Recombinant live feline immunodeficiency virus and proviral dna vaccines
WO1998003669A2 (en) * 1996-07-22 1998-01-29 The Government Of The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Vectors for inhibiting hiv and tumor growth
JP2001513643A (ja) * 1997-03-06 2001-09-04 ウーベルラ、クラウス レンチウイルスをベースとするベクター及びベクター系
GB9704977D0 (en) * 1997-03-11 1997-04-30 Univ Glasgow FIV vaccine
EP1003894A2 (en) * 1997-07-18 2000-05-31 Chiron Corporation Lentiviral vectors

Also Published As

Publication number Publication date
CA2314683A1 (en) 1999-06-24
EP1037669A4 (en) 2003-04-02
EP1037669A1 (en) 2000-09-27
AU749059B2 (en) 2002-06-20
WO1999030742A1 (en) 1999-06-24
JP2002508338A (ja) 2002-03-19
AU1803599A (en) 1999-07-05

Similar Documents

Publication Publication Date Title
JP4190579B2 (ja) 非分裂細胞への核酸運搬のためのベクターおよび使用方法
JP4640742B2 (ja) 高力価で安全な組換えレンチウイルスベクター作成の方法及び手段
CA2328404C (en) Novel lentiviral packaging cells
WO1997012622A9 (en) Vector and method of use for nucleic acid delivery to non-dividing cells
JP2002510199A (ja) レンチウイルスをベースにした遺伝子転移ベクター
CN101663397B (zh) 用于基因治疗的载体
JPH10507905A (ja) ヒト血清による溶解耐性生産者細胞系で生産されるレトロウイルスベクター
AU749059B2 (en) Therapeutic use of lentiviral vectors
WO2024243073A1 (en) Anti-codon engineered suppressor transfer rnas
JP2001501815A (ja) 非分裂細胞への形質導入が可能なレトロウイルスベクター
WO1999019496A1 (en) Inhibition of human immunodeficiency virus (hiv-1) replication
CA2233867C (en) Vector and method of use for nucleic acid delivery to non-dividing cells
WO1998026060A2 (en) Materials and methods for gene transfer
AU758600B2 (en) Vector and method of use for nucleic acid delivery to non-dividing cells
WO1999025862A9 (en) Chimeric viral packaging signal without gag gene sequences

Legal Events

Date Code Title Description
PA0105 International application

Patent event date: 20000612

Patent event code: PA01051R01D

Comment text: International Patent Application

PG1501 Laying open of application
PC1203 Withdrawal of no request for examination
WITN Application deemed withdrawn, e.g. because no request for examination was filed or no examination fee was paid